Business Context and Reporting Period
Company: Nektar Therapeutics
Filing Type: Form 10-Q (Quarterly Report)
Period Ended: September 30, 2006
Business Overview: Nektar is a biopharmaceutical company focused on drug delivery technologies, specifically Nektar Pulmonary Technology and Nektar Advanced PEGylation Technology. The company's primary revenue driver is its partnership with Pfizer Inc. for the manufacturing and supply of Exubera (inhaled insulin), which received regulatory approval in January 2006. The company is currently in a pre-profitability stage with significant accumulated deficits.
Key Financial Metrics
| Metric (in thousands) | Three Months Ended Sep 30, 2006 | Nine Months Ended Sep 30, 2006 | Balance Sheet (Sep 30, 2006) |
|---|---|---|---|
| Total Revenue | $58,632 | $147,814 | - |
| Net Loss | $(19,604) | $(115,906) | - |
| Loss Per Share (Basic/Diluted) | $(0.22) | $(1.29) | - |
| Cash and Cash Equivalents | - | - | $157,668 |
| Total Investments (Short & Long Term) | - | - | $333,282 |
| Total Current Assets | - | - | $546,432 |
| Total Current Liabilities | - | - | $95,329 |
| Long-Term Debt (Convertible Notes) | - | - | $381,627 |
| Accumulated Deficit | - | - | $(1,018,138) |
Liquidity: As of September 30, 2006, the company held approximately $491.0 million in cash, cash equivalents, and investments in marketable securities. Management forecasts sufficient cash to meet net operating expense requirements through at least the end of 2008.
Material Changes vs. Prior Period
- Revenue Growth: Total revenue increased 61% for the three months ended September 30, 2006, compared to the same period in 2005 ($58.6M vs. $36.4M). For the nine-month period, revenue increased 58% ($147.8M vs. $93.4M).
- Revenue Composition Shift: Product sales and royalty revenue surged 391% (three months) and 382% (nine months) due to the commercial launch of Exubera and manufacturing reimbursements from Pfizer. Conversely, contract research revenue declined 36% (three months) and 29% (nine months) as Pfizer transitioned from research agreements to commercial manufacturing.
- Operating Expenses: General and Administrative (G&A) expenses increased significantly, up 32% for the quarter and 102% for the nine-month period. This increase was primarily driven by stock-based compensation (including executive severance) and lease termination costs related to the wind-down of UK operations.
- Net Loss: While revenue increased, the net loss for the nine-month period widened to $115.9 million from $76.9 million in the prior year, largely due to increased G&A expenses and the adoption of SFAS 123R (share-based compensation accounting).
Guidance, Outlook, Risks, and Unusual Items
Management Commentary and Outlook
- Exubera Commercialization: The company's future profitability is heavily dependent on the commercial success of Exubera. Pfizer announced in October 2006 that the expanded commercial roll-out to primary care physicians, originally scheduled for November 2006, would be delayed until January 2007 due to manufacturing scale-up issues.
- Manufacturing: Nektar remains the exclusive manufacturer of Exubera Inhalation Powder. Pfizer is responsible for filling and packaging but has encountered scale-up challenges. Continued manufacturing execution by both parties is critical.
- Capital Needs: The company expects to continue incurring substantial losses. While current cash reserves are sufficient through 2008, future capital needs depend on the success of Exubera and the timing of partnerships for proprietary products.
Risks and Contingencies
- Customer Concentration: Pfizer Inc. represented 61% of total revenue for the three months ended September 30, 2006, and 61% for the nine-month period. The company is highly dependent on Pfizer's ability to market and sell Exubera.
- Legal Proceedings: On August 1, 2006, Novo Nordisk filed a lawsuit against Pfizer alleging patent infringement regarding inhaled insulin. A hearing for a preliminary injunction to suspend Exubera sales is scheduled for December 4, 2006. A suspension would significantly impact Nektar's revenue.
- Debt Obligations: The company has approximately $418.3 million in long-term indebtedness. $102.6 million of convertible subordinated notes mature in 2007, and $315.0 million mature in 2012. Repayment depends on successful commercialization or refinancing.
- Accounting Changes: The adoption of SFAS 123R in 2006 resulted in significant non-cash stock-based compensation expenses ($25.1 million for the nine months ended Sep 30, 2006), reducing reported net income compared to prior periods.
Investor Verification Checklist
- Exubera Sales Data: Verify Pfizer's actual end-user sales volumes and royalty payments, as these are the primary drivers of future revenue.
- Novo Nordisk Litigation: Monitor the outcome of the patent infringement lawsuit and the December 4, 2006, injunction hearing, as a suspension of sales would be catastrophic.
- Debt Maturity: Assess the company's ability to refinance or repay the $102.6 million in convertible notes maturing in 2007.
- Manufacturing Capacity: Confirm that both Nektar and Pfizer have resolved the scale-up issues delaying the commercial roll-out.
- Stock-Based Compensation: Review the impact of future stock grants and vesting schedules on operating expenses, given the $37.7 million in unrecognized compensation expense.